In the realm of colorectal cancer treatments beyond surgery and radiation, one key question gained prominence in recent years: Is the tumor’s DNA repair system defective, making it “microsatellite unstable”? Around 15 to 20 percent of all tumors have this trait, making them likely candidates for successful immunotherapy.